- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01038258
Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy (PETBreast)
Monitoring Response After The First Chemotherapy Cycle In Newly Diagnosed Breast Cancer As A Guide For Neoadjuvant Therapy
Study Overview
Status
Intervention / Treatment
Detailed Description
The use of neo-adjuvant systemic therapy in women recently diagnosed with breast cancer is growing in popularity based on its proven benefit (1). Pre-operative chemotherapy not only can assist in regards to breast conservation therapy (2) but data suggest prognostic benefits in those subset of patient's obtaining complete pathological response (3,4) .
It is imperative for clinicians to detect as early as possible those patients likely to obtain the desired clinical and /or pathologic response, thus identifying those patients who don't benefit from the first line neoadjuvant treatment so that their treatment can be modified accordingly.
Response to treatment based on clinical data or structural imaging, usually requires several chemotherapeutic cycles to establish degree of effectiveness (5). Lately, FDG-PET/CT has been used in different types of neoplasms, breast cancer among them, to establish early response to treatment (6,7). Recent data has established the usefulness of metabolic analysis via FDG-PET, in separating subgroups of chemotherapy. For such analytical approach, sequential estimation of SUVs (Standardized Uptake Value) have been measured along the duration of the treatment. Reduction in SUVs presumes adequate response to treatment (8), while little or no change in metabolic activity presumes sub-optimal response .
However, no definite consensus has been established in regards to what degree of metabolic response is predictive of the desired clinical benefit, particularly early in the treatment . Establishing such criteria could potentially serve as a guideline for monitoring neoadjuvant treatment. Schelling et al, was able to separate a group of patients that eventually showed either progression of the disease or no clinical response as early as the first course of chemotherapy.
The aim of our study is to establish a simple formula using FDG-PET/CT, as early as the first course of chemotherapy, to stratify patients undergoing neoadjuvant chemotherapy for recently diagnosed breast cancer. Those who will benefit from continuing the same treatment will be regarded as responders versus non-responders, which are those in need of changing strategy.
The primary goal of this study is to correlate the results of FDG-PET/CT performed 15 days after the first course of chemotherapy versus those of clinical assessment and breast MRI obtained after the 3rd course of chemotherapy. At that time, a clinical decision on which therapeutic path to be followed will be made.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00919
- Hospital Auxilio Mutuo Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recently diagnosed breast carcinoma that will receive neoadjuvant chemotherapy based on: Tumors size greater than 2 cms; Locally advanced tumors, Tumors close to or invading chest wall or areola and/or Inflammatory Breast cancer.
- 18 years of age.
- Available for follow-up visits
- Able to comply with study requirements.
- Have signed an IRB approved written informed consent form
Exclusion Criteria:
- Any significant medical or psychiatric illness, which would prevent the patient from giving informed consent or following the study procedures.
- Pregnant and Nursing women.
- No restriction will be placed on the chemotherapy regimen used although we expect that most patients will receive Anthracycline based regimens.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: No arms
|
PET scan and surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pathologic response
Time Frame: After 1st course of chemo and after definitive surgery
|
After 1st course of chemo and after definitive surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fernando Cabanillas, MD, Hospital Auxilio Mutuo Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCAM 07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lobular Breast Carcinoma
-
Auxilio Mutuo Cancer CenterUnknownInfiltrating Duct and Lobular Carcinoma In Situ | Invasive Lobular Breast Carcinoma | Inflammatory Breast CarcinomaPuerto Rico
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaCanada
-
Istituto Oncologico Veneto IRCCSRecruitingPleomorphic Lobular Breast Carcinoma in Situ | Breast Florid Lobular Carcinoma in SituItaly
-
Amy C. DegnimNational Cancer Institute (NCI)RecruitingBreast Atypical Lobular Hyperplasia | Breast Atypical Hyperplasia | Breast Lobular Carcinoma in SituUnited States
-
National Cancer Institute (NCI)CompletedBreast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Invasive Breast CarcinomaUnited States
-
University of UtahRecruitingInvasive Lobular Breast CarcinomaUnited States
-
European Institute of OncologyRecruitingBRCA1 Mutation | BRCA2 Mutation | Lobular Breast Carcinoma | Lobular in Situ Breast CarcinomaItaly
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingBreast Carcinoma | Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Lobular Carcinoma In Situ | Breast Sclerosing AdenosisUnited States
-
NYU Langone HealthUnited States Department of DefenseCompletedAtypical Ductal Breast Hyperplasia | Lobular Carcinoma in Situ (LCIS) | Atypical Lobular Hyperplasia (ALH) of BreastUnited States
-
National Cancer Institute (NCI)CompletedLetrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast CancerHealthy, no Evidence of Disease | Lobular Breast Carcinoma in SituUnited States
Clinical Trials on PET scan after course 1 and surgery after 8 courses
-
University Hospital, GhentUniversity GhentCompletedPrimary Liver CancerBelgium
-
Odense University HospitalUnknown
-
Seoul National University HospitalNational Cancer Center, Korea; Samsung Medical Center; Asan Medical Center; Seoul... and other collaboratorsCompletedBreast NeoplasmsKorea, Republic of
-
Hospital JP GarrahanHospital Pereyra Rosell, Montevideo, UruguayRecruitingPediatric Hodgkin's DiseaseArgentina
-
The Catholic University of KoreaActive, not recruitingLymphoma, Large B-Cell, DiffuseKorea, Republic of
-
Yonsei UniversityCompletedDry Eye | Cataract SurgeryKorea, Republic of
-
Centre Hospitalier Universitaire de NīmesCompletedErectile DysfunctionFrance
-
Peking UniversityPeking University People's Hospital; Beijing Friendship Hospital; Chinese PLA...UnknownGastroesophageal Junction AdenocarcinomaChina
-
Simon BerthelotRecruitingAmbulatory Care | Costs | Quality of Care | Emergency Services, HospitalCanada
-
Lei LiUnknownDeep Venous Thrombosis | Gynecologic Neoplasm | Ankle Motion | Abdominal BreathingChina